{"name":"jCyte, Inc","slug":"jcyte-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNMTcxX1NBN0szYmY3RUt6R3JoTzBKUzNYWXk4NHFGNDRsLTNMbHd6YkdiUUV6T0pTWUlBbGg0SmtBbG55VU5odTFldVZKdEc4VEdzZmJSYjc5TmRpak1SMjlQVVRfNnJsdDhEeDZKNXotOWNKNm04QVVlZW01Z0h0SmNMZHVxSFpWb0FHTUxvVEQ?oc=5","date":"2025-09-01","type":"trial","source":"Orange County Business Journal","summary":"JCyte Launches Phase 2 Study to Treat Rare Eye Disease - Orange County Business Journal","headline":"JCyte Launches Phase 2 Study to Treat Rare Eye Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxPRlVzMzU4X0NfN09yZW5SRjhhZG16WExnOTRJUlBKRm9fTGZVSllMVlg2UUx6aHhmaHFkTklyYjNMM1Zqd2VIeWZncXp1SGphOVFJZWxaT0F3cVVTQXEya1dlSTkxTDBqaE5fdGcxRk82aFJFMkZhR1hBVDVDWWFQTl82UFNOcVIxSk90a0JmVlRGaE8xaFVtVTk5S3hmQUZnYVZkVmlhZHp3bEpYN2QyTlBobjY4NGFBUVFLdlNkUUgxcDJ3Xy1CRXZQN1BObElFdmlDTmkwUWVhMHhwYkVfUlBoaHhsblNFVTRNei1rRVNPaURQby1OUzhlVWlCRG5RWGdBM1lVNm9rMDlhQjl5UGFCOGVTMjBCV2hhTmczbHdnMnUwQjlsRg?oc=5","date":"2025-08-25","type":"trial","source":"businesswire.com","summary":"jCyte Announces Publication of Phase I/IIa Safety Study of Retinal Progenitor Cells in Retinitis Pigmentosa in Frontiers in Cellular Neuroscience - businesswire.com","headline":"jCyte Announces Publication of Phase I/IIa Safety Study of Retinal Progenitor Cells in Retinitis Pigmentosa in Frontiers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPamlFYmZnaHBWOTYxYVZsTnhKNDQ0UzhmbWdKbFFydFM3TlVvUlJ2a18xalI4d20yXy12UUl6MEFWcmNWdWlrMVY3d0piMEdhTkNuZURWYk9PWjc1dFJWcENYYjVyLVNQaHZWQ0hWMlFPcl9wQ25lZDVtTEV2YjE5bElVWG9oU0dTZUtsMm5zYk9QckZVUzEzUmFFemdlN3F5V1lrM05NYTM4TWtwQkJxT3dR?oc=5","date":"2025-08-21","type":"trial","source":"Eyes On Eyecare","summary":"jCyte doses first patients in RP allogeneic cell therapy trial - Eyes On Eyecare","headline":"jCyte doses first patients in RP allogeneic cell therapy trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPUE1WUjFld0NtYWc4anA0MnpCMF8wQXR1bEl1RGxGWUFhVWRWRFF0SDRpSkZ2UjNXU0R2OGNuUHJEbklBX01FTWVlNkl1UF82dGttSGx1MEtmTFIxVndiVzhkTjFYT1BfMS1UdXQ2aHdweDZhc2EtRThTQWhzVlFmWVVFNkVkSWZDM0RGOTNvQUtBYUZpNTRaSTFoeVNjS2hPQmNyd1MydlZieWQzWkN6dzdubzJGSDlHV0RNem5Eemk1ZEFGSDJNdVVfdXlZWkp3UWpnTkxaZHdTUQ?oc=5","date":"2025-08-18","type":"trial","source":"businesswire.com","summary":"jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa - businesswire.com","headline":"jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQc0N4WFV3WE9iTWZWUXJQZ2NndndYTlo0MWlwcUJkQWhBXzVIblRtbUE2UVpGMmY5OEpiOVR3MllsaFZhYy1wMy15VVJMU1JGZ1VHVDR2Y01ielZyVUtsWkVrNnNVTEliZjNCS09MWnZHUE5PR3hnTDF4VWtBZmRrRW1NaEhBZkRPUE9oOXVjOHEyTTNRcE5zMVNHR2FkTXRGUnJxY1ZhMC0xNmRLTDZSWm9oMVQtNnJyQWtXNXpB?oc=5","date":"2025-05-29","type":"pipeline","source":"Eyes On Eyecare","summary":"Ophthalmology Tech Forum to highlight latest trends and advancements - Eyes On Eyecare","headline":"Ophthalmology Tech Forum to highlight latest trends and advancements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQWm5pN3F3Wi1BVzV6eDFuX0FmcDFBV1g4Z3p5Mk5qWUc3SXdiaERQR2I0TlZTTUFSdmF1SlBNbFB4cXNOdzhhbm9ycXkzeEZpNGZVbEdEWDAtR25ZdVQ4bU43bE10SF8zYWh2VGhMbllWX0loTmpMdUsxZXMzQ0pxWHlSQ1hmWDRLNm4zRTQ3bWNHbG1RUkpwU1B3SlNqeVlCeXdwMDMyQ3hkVlVQbnBJV2lKZmRyYXoxckRZaS1FRGkwYnIyNEtCYTBXUHA4azhnS3pXWk5tUFB5dzFRdFRrTEE1T2JDMzJrX3c?oc=5","date":"2025-03-26","type":"pipeline","source":"prnewswire.com","summary":"LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight - prnewswire.com","headline":"LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPRkJLQ0l0M05vSXRrTzFvcDl3aXhDRmU4NzVnalVpaGxRQldGSkxtYXZmemY0WkF1MWp0SEVISVR2dlJ6UFhhQ1FBMUM4bVJNcmdUQ3FtQTExejVCOUx1WWo4Wk9zdWhfWHFObEYwZ0pDM0IxUXVDbEFVSWFuOV91QnVIMG1QVXpRZkstLWJrenJiek4wSkVaQS1kTjNsbGJ1UjdKYVpIQUhwVzQ5VUcydThqNVJqNS1zYnkwa3FoVEtudG9xeTRMdWx6LUVhV01adnpFaEhCbXhwY3A3SURhNFBsOWtvamF2OURMc21TN2sxOWs?oc=5","date":"2024-05-07","type":"trial","source":"GlobeNewswire","summary":"Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight - GlobeNewswire","headline":"Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxPVjBaYkhuUnhrQk9aekFBYjlGSzhMOGRZQlZ4S1NkRUVOSUNsWEZDMDZJMHVKUmx3Q1ZEYTg4ZUtvTTdUbm5Ub0ZPcUpSN2VFQW1VeFRid2E4aWJSUlBBUUVXeURScXdZMDNoTktkNXJLLWM0aF94aEpRQTljOVhuM0VCZWpKYkpoWUhheVVZZW9wdGdjWUhUM0ZmWTBMZzFpVjVqRHpYdzNRd19hVS1JRW85SzBEOWkyOUdyMkpiZ3NmX2lrcHJmWlkwVmd6eTAwU0VjZzQ0cHVxOVNVR3pVd3NMS1dFNFhYcUMwejh4MDBhRk1lbXhORVlELUVfYllOX3BDYkhlOHlVY0lKblBPZXZBaTUzLTFOUUFLVkJIdTBCbzVSV2xSQ0xrOXkwQWtaWFEzeEVpSXZYOEJzOWkwSmFR?oc=5","date":"2024-02-21","type":"regulatory","source":"businesswire.com","summary":"jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell - businesswire.com","headline":"jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}